2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership

2/2 药物开发和能力建设：UCR/CoH-CCC 合作伙伴关系

• 批准号: 10762287
• 负责人: ERNEST MARTINEZ
• 金额: $ 135.85万
• 依托单位: UNIVERSITY OF CALIFORNIA RIVERSIDE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-22 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10762287
• 关键词: Address; Affect; African; African American; African American population; American; Award; Bioinformatics; Black race; California; Cancer Center Planning Grant; Catchment Area; Cell Line; City of Hope Comprehensive Cancer Center; Clinical; Collaborations; Communities; Comprehensive Cancer Center; Conduct Clinical Trials; Core Facility; County; Crowding; Disparity; Drug Design; Drug Targeting; Economics; Education; Engineering; Ensure; Equity; European; FDA approved; Faculty; Fellowship; Fostering; Funding; Goals; Grant; Growth; Hispanic Americans; Incubators; Individual; Infrastructure; Institution; Investments; Joints; Laboratories; Latino; Latino Population; Los Angeles; Malignant Neoplasms; Master of Science; Mentors; Mentorship; Minority; Neighborhoods; Not Hispanic or Latino; Pharmaceutical Preparations; Phase; Physicians; Population; Population Heterogeneity; Postdoctoral Fellow; Prognosis; Reporting; Research Personnel; Resources; Scientist; Section 8; Site; Societies; Students; System; Testing; Therapeutic Agents; Therapeutic Trials; Toxic effect; Training; Training Programs; Translations; United States; United States National Institutes of Health; Universities; Work; anticancer research; cancer health disparity; clinical trial participant; commercialization; disparity elimination; disparity reduction; drug development; drug discovery; malignant breast neoplasm; manufacturing facility; medical schools; men; minority communities; news; next generation; novel therapeutics; phase 1 testing; programs; screening; small molecule inhibitor; success; synergism; therapeutic development; women of color

The United States (U.S.) has led the world in drug discovery for over 50 years. While this is a significant accomplishment, U.S. drugs have been almost exclusively optimized and tested in non-Hispanic European- Americans and been minimally evaluated in men- or women-of-color. As a result, drugs that work well in non- Hispanic European-Americans (Anglos), may have unexpected toxicity or decreased efficacy in most of the world’s population. Disparities in U.S. drug development occur throughout the entire drug discovery pipeline. Only a small number of basic scientists are Latino/Hispanic- or African-American. Initial drug development and optimization takes place in cell lines derived from Anglos. Less than 2% of physicians conducting clinical trials are Latino/Hispanic- or African-American6. Most clinical trials participants are Anglos. Yet, new drugs are FDA approved for Latinos/Hispanics- and African-Americans/Africans without sufficient testing. It is unacceptable that drugs are developed by, and optimized for, only a fraction of our citizens. In this U54 partnership we aim to develop the resources, infrastructure, and training to mentor the next generation of researchers that reflect the diversity of our Catchment Area. Building on our successful P20 grant, here in this U54 partnership, UCR and CoHCCC aim to develop the collaborations, resources, and training programs to reduce disparities in drug development throughout the entire drug development pipeline. Our goal is for this program to become a focal point for UCR and CoHCCC to mentor and train a diverse force of cancer biologists and address the disparities in cancer therapeutics and drug development. Already, our P20 has fostered joint R01 grants, K01 grants, and pre-/post-doctoral fellowships. Both institutions are highly committed - CoHCCC contributed over $800K to our P20 grant and will contribute $250K/year to ensure the success of this U54 partnership. Aim 1 will strengthen UCR’s cancer research capacity and develop the resources to increase UCR/CoHCCC’s ability to jointly develop therapeutic agents optimized for the diverse populations in our catchment area. Aim 2 will increase the capacity of UCR and CoHCCC to jointly develop drugs that target disparities in survival affecting the diverse individuals living in our Southern California communities. Aim 3 will provide the training, opportunity, and mentorship to ensure that the next generation of therapeutic scientists and clinical trialists reflect the diversity of Southern California.

美国（美国）领导着全世界的毒品发现超过50年。虽然这很重要 成就，在非西班牙裔欧洲 - 美国人，在男人或彩色女性中进行最少评估。结果，在非 - 西班牙裔欧洲人（盎格鲁人），大多数人可能具有意想不到的毒性或效率降低 世界人口。美国药物开发的差异发生在整个药物发现管道中。 只有少数基本科学家是拉丁裔/西班牙裔或非裔美国人。最初的药物开发和 优化发生在来自盎格鲁人的细胞系中。进行临床试验的医师不到2％ 是拉丁裔/西班牙裔或非裔美国人。大多数临床试验参与者都是盎格鲁人。但是，新药是FDA 在没有足够测试的情况下批准了拉丁美洲人/西班牙裔和非裔美国人/非洲人/非洲人/非洲人。是不可接受的 药物是由我们公民中一小部分开发的，并优化了。在这个U54合作伙伴中，我们的目标是 为反映的下一代研究人员开发资源，基础设施和培训 我们集水区的多样性。以我们成功的P20赠款为基础，在U54合作伙伴关系中，UCR和 COHCCC旨在制定合作，资源和培训计划以减少药物的分配 整个药物开发管道的发展。我们的目标是使该计划成为焦点 UCR和COHCCC的精神和培训癌症生物学家的潜水力量的观点，并解决分布 在癌症治疗和药物开发中。我们的P20已经培养了R01赠款，K01赠款和 前/博士后奖学金。这两个机构都非常投入 - Cohccc为我们的 P20赠款将捐款25万美元/年，以确保该U54合作伙伴关系的成功。目标1将加强 UCR的癌症研究能力并开发了提高UCR/CoHCCC共同发展的能力的资源 治疗剂针对我们集水区的潜水员人群进行了优化。 AIM 2将增加容量 UCR和CoHCCC的共同开发针对生存的药物，影响潜水员个体 生活在我们南加州社区。 AIM 3将提供培训，机会和心态 确保下一代的治疗科学家和临床试验者反映了南方的多样性 加利福尼亚。